Thibault Veyron: Optimizing Bivalirudin Treatment in HIT
Thibault Veyron, Medical Doctoral Researcher at CHUV – Lausanne University Hospital, shared a post on LinkedIn:
“A patient’s platelets are dropping. The drug meant to protect them is now the threat.
That’s heparin-induced thrombocytopenia (HIT). One of the main ways to treat it is bivalirudin, a drug that is hard to manage and dosed by guidelines that rarely match what happens at the bedside.
For the past two years, that gap has been the subject of my MD thesis at CHUV: looking at how we actually manage bivalirudin in HIT, and how the guidelines could be revised to better reflect real-world practice.
On Thursday, November 19, I presented this work at the Swiss Oncology & Hematology Congress (SOHC 2026). Five minutes, one poster, and a lot of case files behind it.
None of it would have happened without the Hematology Department at CHUV. Thank you for your guidance, your patience and your time.
Next steps: finishing the manuscript and getting it published.”

Stay updated with Hemostatis Today.
-
Nov 21, 2026, 12:44Paulus Kirchhof: Left Atrial Appendage Occlusion vs DOACs
-
Nov 21, 2026, 12:19Jiyeon Kim: Human Platelet Lysate – Advancing Cell Therapy and Space Research
-
Nov 21, 2026, 12:13Chaza Alaji: DVT in Early Pregnancy – Why Anticoagulation Decisions Matter
-
Nov 21, 2026, 12:06Salih Ehsan: Why Iron Therapy May Not Work
-
Nov 21, 2026, 11:59Edward Lee Carter: DOACs vs Warfarin for LV Thrombus – Are We Getting Closer to an Answer?
-
Nov 21, 2026, 11:50Abdul Mannan: When G6PD Testing Misleads During Acute Hemolysis
-
Nov 21, 2026, 11:36Emma Copperwaite: Transforming the Transfusion Pathway Through Digital Innovation
-
Nov 21, 2026, 11:28Nathan Connell: Rethinking the Role of Factor V in Hemostasis
-
Nov 21, 2026, 11:16Jecko Thachil: Optimizing Corticosteroid Therapy in ITP